两次序贯高强度聚焦超声消融治疗大型良性甲状腺结节
研究纳入50例大结节(基线体积≥20 mL且直径≤50 mm)患者,31例单次消融(I组)、19例两次序贯消融(II组)。II组6个月体积缩小率显著更高(56.74±11.47% vs 43.49±12.03%,p=0.004),序贯消融是6个月VRR的独立决定因素(OR=13.936,95%CI=1.738-197.399,p=0.036)。两组疼痛及声带麻痹、皮肤烧伤、恶心呕吐发生率无显著差异(p>0.05)。
要点
- 两次序贯HIFU消融较单次消融使大结节6个月体积缩小率更高(56.74±11.47% vs 43.49±12.03%,p=0.004)。
- 序贯消融是6个月VRR的独立决定因素(OR=13.936,95%CI=1.738-197.399,p=0.036)。
- 两组疼痛严重程度及声带麻痹、皮肤烧伤、恶心呕吐发生率无显著差异(p>0.05)。
核心结论
- 在大型良性甲状腺结节中,两次序贯HIFU消融较单次消融获得更好的6个月治疗疗效,且未增加治疗相关副作用风险。
研究设计与样本
- 研究纳入50例大结节(基线体积≥20 mL且直径≤50 mm)患者,31例(62.0%)接受单次消融(I组),19例(38.0%)接受两次序贯消融(II组);比较结节缩小(VRR)、消融中及消融后疼痛评分、声带麻痹(VCP)、皮肤烧伤、恶心呕吐发生率。
诊断标准与关键数值
- II组6个月VRR为56.74±11.47%,I组为43.49±12.03%(p=0.004)。
- 序贯消融为6个月VRR的独立决定因素(OR=13.936,95%CI=1.738-197.399,p=0.036)。
- II组总能量及治疗时间显著多于I组(p<0.001和p=0.001)。
- II组单位结节体积总能量显著大于I组(1.01 kJ/mL vs 0.57 kJ/mL,p<0.001)。
临床应用与阅片要点
- 对大型良性甲状腺结节(基线体积≥20 mL且直径≤50 mm),两次序贯HIFU消融可获得比单次消融更好的6个月体积缩小效果。
- 序贯消融需要更长的治疗时间及更大剂量的哌替啶和地西泮。
- 两组疼痛严重程度及声带麻痹、皮肤烧伤、恶心呕吐发生率无显著差异(p>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: High-intensity focused ultrasound (HIFU) ablation is a promising treatment for benign thyroid nodules but single application is less effective in larger-sized nodules. We aimed to assess the efficacy and safety of two sequential applications in larger-sized nodules.
METHODS: Fifty patients underwent ablation of a large-sized nodule (baseline volume ≥ 20 mL and diameter ≤ 50 mm). Thirty-one (62.0%) patients underwent single application (group I) while 19 (38.0%) underwent two sequential applications (group II). Nodule shrinkage (by volume reduction ratio or VRR), pain scores during and after ablation, and rate of vocal cord palsy (VCP), skin burn, and nausea/vomiting were compared between the two groups. t test or the Mann-Whitney U test was used for continuous variables while chi-square test was used for categorical variables. To determine factors for VRR, multivariate analysis was done by logistic regression analysis.
RESULTS: Total energy delivered and treatment time were significantly more in group II (p < 0.001 and p = 0.001, respectively). Total energy per nodule volume (kJ/mL) was also significantly greater in group II (1.01 kJ/mL vs. 0.57 kJ/mL, p < 0.001). The 6-month VRR was significantly greater in group II (56.74 ± 11.47% vs. 43.49 ± 12.03%, p = 0.004). Pain severity and rates of VCP, skin burn, and nausea/vomiting were comparable between the two groups (p > 0.05). Sequential application was an independent determinant of 6-month VRR (OR = 13.936, 95% CI = 1.738-197.399, p = 0.036).
CONCLUSIONS: Sequential application led to better 6-month treatment efficacy than single application in large-sized nodules. Patients undergoing sequential application are not at greater risks of treatment-related side effects afterwards.
KEY POINTS: • Sequential application produces better 6-month efficacy over single application for large-sized nodules. • Sequential HIFU application is well-tolerated and safe in patients with large-sized nodules. • Sequential application takes longer and requires larger amount of pethidine and diazepam.
引用
- Lang BHH, Woo YC, Chiu KW, et al. Two sequential applications of high-intensity focused ultrasound (HIFU) ablation for large benign thyroid nodules. Eur Radiol. 2019. PMID: 30778718. doi:10.1007/s00330-019-06021-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。